ketanserin has been researched along with Arteriosclerosis in 21 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The rationale for ketanserin therapy in hypertension is reviewed against the background of known physiological and pathophysiological effects of serotonin." | 8.77 | The rationale for ketanserin therapy in hypertension. ( Hansson, L; Hedner, T, 1987) |
| "To determine whether ketanserin, an antagonist at the serotonin receptor, prevents important vascular events such as death, myocardial infarction, major stroke, and amputation of a leg in patients with claudication." | 5.06 | Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. ( , 1989) |
| "Publication of the results of a large-scale randomized control trial (RCT) of the anti-serotonin drug ketanserin in patients with intermittent claudication offers an opportunity to examine the validity of retrospective subgroup analyses to generate hypotheses for further validation." | 5.06 | Retrospective analyses for hypothesis generation. A commentary on the PACK trial (prevention of atherosclerotic complications with ketanserin). ( Chalmers, TC; Murray, GD, 1989) |
| "The rationale for ketanserin therapy in hypertension is reviewed against the background of known physiological and pathophysiological effects of serotonin." | 4.77 | The rationale for ketanserin therapy in hypertension. ( Hansson, L; Hedner, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (52.38) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaumann, AJ | 1 |
| Frenken, M | 1 |
| Posival, H | 1 |
| Brown, AM | 1 |
| Geerling, RA | 1 |
| de Bruin, RW | 1 |
| Scheringa, M | 1 |
| Bonthuis, F | 1 |
| IJzermans, JN | 1 |
| Marquet, RL | 1 |
| Verstraete, M | 1 |
| Frishman, WH | 1 |
| Grewall, P | 1 |
| Ishida, T | 1 |
| Kawashima, S | 1 |
| Sakoda, T | 1 |
| Shimokawa, Y | 1 |
| Miwa, Y | 1 |
| Inoue, N | 1 |
| Ueyama, T | 1 |
| Shiomi, M | 1 |
| Akita, H | 1 |
| Yokoyama, M | 1 |
| Belousov, IuB | 1 |
| Krivonkin, KIu | 1 |
| Neri, MS | 1 |
| Stagnaro, S | 1 |
| Janicek, MJ | 1 |
| Meyerovitz, M | 2 |
| Harrington, DP | 2 |
| Hollenberg, NK | 3 |
| Doyle, AE | 1 |
| Janicek, M | 1 |
| Grassi, CJ | 1 |
| Callahan, MB | 1 |
| Sandor, T | 1 |
| Whittemore, A | 1 |
| Mannick, J | 1 |
| Hansson, L | 1 |
| Hedner, T | 1 |
| Chalmers, TC | 2 |
| Kalkman, HO | 1 |
| Neumann, V | 1 |
| Brauner, V | 1 |
| de Leeuw, PW | 1 |
| Murray, GD | 1 |
| Reijnders, PJ | 1 |
| Di Giovanni, V | 1 |
| Colli, R | 1 |
| Heistad, DD | 1 |
| Armstrong, ML | 1 |
| Marcus, ML | 1 |
| Piegors, DJ | 1 |
| Mark, AL | 1 |
3 reviews available for ketanserin and Arteriosclerosis
| Article | Year |
|---|---|
Serotonin and the heart.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Cardiovascular Diseases; Endothe | 2000 |
Age-related effects of 5-HT2 antagonists.
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Humans; Hypertension; Ketanserin; Middle Aged | 1991 |
The rationale for ketanserin therapy in hypertension.
Topics: Animals; Arteriosclerosis; Blood Platelets; Blood Pressure; Hemodynamics; Hormones; Humans; Hyperten | 1987 |
6 trials available for ketanserin and Arteriosclerosis
| Article | Year |
|---|---|
The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications.
Topics: Aged; Anti-Arrhythmia Agents; Arteriosclerosis; Diuretics; Double-Blind Method; Drug Interactions; F | 1996 |
Arterial response to ketanserin and aspirin in patients with advanced peripheral atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Arteries; Arteriosclerosis; Aspirin; Female; Humans; Ketanserin; Mal | 1992 |
Atherosclerosis, peripheral arterial disease and the vascular response to ketanserin.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Female; Hemodynamics; Humans; Injections, Intra-Ar | 1990 |
Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
Topics: Adult; Amputation, Surgical; Arteriosclerosis; Cardiovascular Diseases; Cause of Death; Cerebrovascu | 1989 |
Prevention of atherosclerotic complications with ketanserin.
Topics: Arteriosclerosis; Clinical Trials as Topic; Humans; Ketanserin | 1989 |
Retrospective analyses for hypothesis generation. A commentary on the PACK trial (prevention of atherosclerotic complications with ketanserin).
Topics: Adult; Arteriosclerosis; Diuretics; Drug Interactions; Female; Humans; Intermittent Claudication; Ke | 1989 |
12 other studies available for ketanserin and Arteriosclerosis
| Article | Year |
|---|---|
Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors.
Topics: Adult; Arteriosclerosis; Binding, Competitive; Cardiomyopathy, Dilated; Cloning, Molecular; Coronary | 1994 |
Ketanserin reduces graft arteriosclerosis after allogeneic aorta transplantation in rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Pressure; Ketanserin; Male; Platelet Aggregation; Rats; Rats | 1996 |
Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries.
Topics: Animals; Arteriosclerosis; Calcium; Coronary Vessels; Dose-Response Relationship, Drug; Female; In V | 2001 |
[Role of serotonin and its receptors in the pathogenesis of arterial hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Brain; Humans; Hypertension; Ketanserin; Recepto | 1992 |
[Ketanserin, an antagonist of 5-HT2 serotoninergic receptors and free-radical scavenger].
Topics: Aged; Arteriosclerosis; Auscultation; Drug Evaluation; Female; Free Radical Scavengers; Humans; Keta | 1992 |
Large and small vessel responses to serotonin in the peripheral circulation.
Topics: Arteriosclerosis; Humans; Ketanserin; Muscle, Smooth, Vascular; Piperidines; Regional Blood Flow; Se | 1985 |
Prevention of atherosclerotic complications with ketanserin.
Topics: Arteriosclerosis; Coronary Disease; Humans; Ketanserin; Research Design | 1989 |
Supersensitivity of atherosclerotic rabbit aorta to ergometrine is mediated by 5-HT2 receptors.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cyproheptadine; Ergonovine; In Vitro Techni | 1989 |
Can atherosclerotic complications be prevented?
Topics: Arteriosclerosis; Coronary Disease; Humans; Hyperlipidemias; Hypertension; Ketanserin | 1989 |
[Observations with ketanserin].
Topics: Arteriosclerosis; Humans; Hypertension; Ketanserin | 1989 |
Peripheral arterial diseases: treatment with ketanserin as i.v. infusion. An open study in 20 patients.
Topics: Arteriosclerosis; Humans; Infusions, Parenteral; Ketanserin; Piperidines; Regional Blood Flow | 1985 |
Potentiation of vasoconstrictor responses to serotonin in the limb of atherosclerotic monkeys.
Topics: Animals; Arteriosclerosis; Hindlimb; Hypercholesterolemia; Ketanserin; Macaca fascicularis; Methyser | 1986 |